NASDAQ · DARE
Dare Bioscience, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for DARE: Nov 12, 2026
Dare Bioscience, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.09. The reported EPS for the same quarter last year was $-0.28.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.09 | $0.10 | $-0.27 | 2 |
| Dec 2026 | $-0.20 | $-0.16 | $-0.24 | 2 |
| Mar 2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Jun 2027 | $-0.10 | $-0.10 | $-0.10 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · Zacks- RTTNews · Oct 13, 9:54 AM EDTDaré Bioscience Launches CEO Corner Series To Update Investors On Women's Health Pipeline(RTTNews) – Daré Bioscience, Inc. (DARE) has launched CEO Corner, a new video series featuring Founder, President and CEO Sabrina Martucci Johnson to provide investors with insights into the company's women's health portfolio, corporate strategy and development programs.
- RTTNews · Oct 8, 1:20 PM EDTDaré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 Study(RTTNews) – Daré Bioscience (DARE) said clinical data from a Phase 1 study of its investigational Sildenafil Cream, 3.6%, will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) in Orlando, Florida.
- RTTNews · Sep 14, 10:34 AM EDTDaré Bioscience Reports Phase 1 Sildenafil Cream Data Showing Lower Systemic Exposure(RTTNews) – Daré Bioscience, Inc. (DARE) announced the peer-reviewed publication of Phase 1 clinical data evaluating its proprietary Sildenafil Cream, 3.6% in healthy adult men, with results showing substantially lower systemic exposure compared with a 50 mg oral dose of sildenaf
- RTTNews · Aug 29, 6:34 AM EDTWhy Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories(RTTNews) – The Virtual Investor "Why Now" On-Demand Conference, hosted by Virtual Investor Co. in partnership with JTC Team, wrapped up on August 27, 2026. The program is designed to give investors and analysts direct access to management teams, each presenting why now is the ri
- The Motley Fool · Aug 20, 4:55 PM EDTDaré Bioscience (DARE) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 13, 5:15 PM EDTDare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue EstimatesDare Bioscience (DARE) delivered earnings and revenue surprises of +39.39% and +1,775.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Aug 12, 8:25 AM EDTMilestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue EstimatesMilestone Pharmaceuticals (MIST) delivered earnings and revenue surprises of -16.67% and -30.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- The Motley Fool · May 21, 5:31 PM EDTDaré (DARE) Q4 2025 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- The Motley Fool · May 15, 1:18 PM EDTDaré (DARE) Q1 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · May 12, 5:40 PM EDTOrchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue EstimatesOrchestra BioMed Holdings, Inc. (OBIO) delivered earnings and revenue surprises of +16.98% and -94.27%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 26, 5:20 PM EDTDare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue EstimatesDare Bioscience (DARE) delivered earnings and revenue surprises of +91.67% and -28.41%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 9, 8:25 AM EDTDianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue EstimatesDianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -45.28% and -45.28%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Dare Bioscience, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.